Sparsentan (Filspari) becomes first approved treatment for focal segmental glomerulosclerosis

1. Sparsentan (Filspari) becomes the first approved treatment specifically for focal segmental glomerulosclerosis.

2. Clinical trial data show meaningful reductions in proteinuria, a key marker of disease progression.

The FDA granted full approval to sparsentan (Filspari) on April 13, 2026, for the reduction of proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis. For many patients, treatment has historically relied on off label therapies with mixed results. This approval marks a shift toward more targeted care. Phase 3 DUPLEX study data showed rapid and sustained reductions in proteinuria compared with irbesartan. That is important because proteinuria is closely linked to disease progression. The approval reflects a broader move toward disease specific treatment strategies in nephrology. The expanded FDA indication includes patients aged 8 and older without nephrotic syndrome. This expands access to a group that previously had limited options. Common adverse reactions include peripheral edema, hypotension, and hyperkalemia. Monitoring will be important as use becomes more widespread. Long term outcomes such as kidney function preservation will be closely followed. Patient groups have described the approval as a major milestone. It reflects years of progress in understanding this rare disease. Real world data will help determine how these results translate into everyday care.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.